Ligand Pharmaceuticals Incorporated Share Price

Equities

LGND

US53220K5048

Pharmaceuticals

Real-time Estimate Cboe BZX 18:54:07 18/06/2024 BST 5-day change 1st Jan Change
80.38 USD -0.33% Intraday chart for Ligand Pharmaceuticals Incorporated +0.14% +12.31%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 138M 10.85B Sales 2025 * 157M 12.39B Capitalization 1.45B 114B
Net income 2024 * 92M 7.24B Net income 2025 * 50M 3.93B EV / Sales 2024 * 10.5 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 9.2 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
25 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.7%
More Fundamentals * Assessed data
Dynamic Chart
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults CI
Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views MT
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83 MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024 CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference CI
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics CI
More news
1 day-0.30%
1 week+0.14%
Current month-5.68%
1 month-7.41%
3 months+11.19%
6 months+15.92%
Current year+12.31%
More quotes
1 week
77.58
Extreme 77.58
81.89
1 month
77.43
Extreme 77.425
88.73
Current year
67.53
Extreme 67.53
94.57
1 year
49.24
Extreme 49.24
94.57
3 years
49.24
Extreme 49.24
169.98
5 years
49.24
Extreme 49.24
219.75
10 years
41.99
Extreme 41.99
278.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 28/02/07
Director of Finance/CFO 53 31/10/22
President 49 05/08/15
Members of the board TitleAgeSince
Chairman 74 28/02/03
Director/Board Member 74 31/01/11
Director/Board Member 64 03/08/08
More insiders
Date Price Change Volume
18/06/24 80.22 -0.53% 39 930
17/06/24 80.64 +0.72% 94,894
14/06/24 80.06 -1.57% 85,117
13/06/24 81.34 +1.48% 71,823
12/06/24 80.15 +0.06% 80,608

Delayed Quote Nasdaq, June 18, 2024 at 06:37 pm

More quotes
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
80.64 USD
Average target price
116.8 USD
Spread / Average Target
+44.84%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW